SyntekaBio, Inc. (KOSDAQ:226330)
South Korea · Delayed Price · Currency is KRW 1,239.00
+17.00 (1.39%)
At close: Sep 11, 2026
SyntekaBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,086 | 3,429 | 120.89 | 123.41 | 243.99 | 316.66 | |
Revenue Growth | 132.30% | 2736.72% | -2.04% | -49.42% | -22.95% | -48.06% |
Cost of Revenue | 1.65 | 4.31 | 3.91 | 2.48 | 10.96 | 15.24 |
Gross Profit | 3,084 | 3,425 | 116.97 | 120.92 | 233.04 | 301.42 |
Selling, General & Admin | 8,218 | 9,863 | 9,253 | 7,477 | 7,456 | 4,828 |
Research & Development | 3,540 | 2,290 | 2,937 | 3,225 | 3,177 | 3,101 |
Amortization of Goodwill & Intangibles | 99.96 | 100.78 | 101.99 | 181.75 | 148.8 | 111.18 |
Other Operating Expenses | 123.99 | 246.62 | 233.5 | 187.25 | 149.85 | 106.24 |
Operating Expenses | 13,618 | 14,190 | 14,387 | 12,397 | 12,025 | 9,193 |
Operating Income | -10,534 | -10,765 | -14,270 | -12,276 | -11,792 | -8,891 |
Interest Expense | -2,402 | -2,841 | -2,008 | -375.74 | -1,251 | -254.17 |
Interest & Investment Income | 171.31 | 26.73 | 349.12 | 1,171 | 971.76 | 374.41 |
Currency Exchange Gain (Loss) | 19.92 | 3.13 | -8.39 | -0.35 | 2.59 | 0.22 |
Other Non Operating Income (Expenses) | 2,676 | 720.52 | 8,895 | 758.7 | 7,583 | -6,032 |
EBT Excluding Unusual Items | -10,068 | -12,855 | -7,042 | -10,723 | -4,486 | -14,803 |
Gain (Loss) on Sale of Assets | -25.27 | -25.27 | -5.73 | - | 0.13 | - |
Asset Writedown | -85.33 | -46.91 | -1.26 | -72 | -20.25 | - |
Other Unusual Items | -1,829 | -4,450 | -163.97 | -603.08 | - | - |
Pretax Income | -12,008 | -17,378 | -7,213 | -11,398 | -4,506 | -14,803 |
Net Income | -12,008 | -17,378 | -7,213 | -11,398 | -4,506 | -14,803 |
Net Income to Common | -12,008 | -17,378 | -7,213 | -11,398 | -4,506 | -14,803 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 20 | 16 | 15 | 14 | 14 | 13 |
Shares Outstanding (Diluted) | 20 | 16 | 15 | 14 | 14 | 13 |
Shares Change | 31.53% | 2.16% | 6.52% | 5.94% | 0.37% | 1.65% |
EPS (Basic) | -598.39 | -1115.48 | -473.00 | -796.14 | -333.47 | -1099.43 |
EPS (Diluted) | -598.39 | -1115.48 | -473.00 | -796.14 | -333.47 | -1099.43 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -10,841 | -10,661 | -16,216 | -17,442 | -16,899 | -13,520 |
Free Cash Flow Per Share | -540.23 | -684.32 | -1063.33 | -1218.35 | -1250.52 | -1004.13 |
Gross Margin | 99.95% | 99.87% | 96.76% | 97.99% | 95.51% | 95.19% |
Operating Margin | -341.33% | -313.91% | -11804.01% | -9947.91% | -4832.99% | -2807.83% |
Profit Margin | -389.09% | -506.76% | -5966.88% | -9235.91% | -1846.96% | -4674.69% |
Free Cash Flow Margin | -351.27% | -310.88% | -13413.89% | -14133.89% | -6926.24% | -4269.46% |
EBITDA | -8,587 | -8,741 | -12,015 | -10,514 | -10,319 | -7,733 |
EBITDA Margin | -278.25% | -254.90% | - | - | - | - |
D&A For EBITDA | 1,947 | 2,023 | 2,254 | 1,762 | 1,473 | 1,158 |
EBIT | -10,534 | -10,765 | -14,270 | -12,276 | -11,792 | -8,891 |